COLL — Collegium Pharmaceutical, Inc.

Summary of Collegium Pharmaceutical, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Full-Year 2025 Results:
  • Net revenues reached a record $780.6 million, up 24% year-over-year.
  • Adjusted EBITDA was $460.5 million, a 15% increase year-over-year.
  • Cash generated from operations exceeded $329 million, ending the year with $386.7 million in cash and equivalents.
  • GAAP net income for the year was $62.9 million, down 9% due to a one-time loss on debt extinguishment.
  • Non-GAAP adjusted earnings per share were $7.42, compared to $6.45 in the prior year.
• Q4 2025 Results:
  • Total net product revenues were $205.4 million, up 13% year-over-year.
  • Jornay PM revenue was $45.9 million, a 57% increase year-over-year.
  • Pain portfolio revenues totaled $631.7 million for the year, up 6% year-over-year.

2. Strategic Updates and Business Highlights

• Growth Initiatives:
  • Continued momentum for Jornay PM, with prescriptions growing 20% year-over-year and reaching an all-time high in prescribers.
  • Successful back-to-school season contributed to strong sales.
  • Expanded sales force and marketing initiatives are expected to drive further growth in 2026.
• Pain Portfolio:
  • The pain portfolio remains robust, with all three core medicines showing growth.
  • New agreements with Hikma Pharmaceuticals for authorized generics of Nucynta are expected to enhance profitability.
• Capital Deployment:
  • Closed a $980 million syndicated credit facility, improving financial flexibility and interest terms.
  • Returned $25 million to shareholders via a share repurchase program.

3. Forward Guidance and Outlook

• 2026 Financial Guidance:
  • Expected total product revenues between $805 million and $825 million, reflecting a 4% increase year-over-year.
  • Jornay PM revenue projected at $190 million to $200 million, indicating over 30% growth.
  • Anticipated adjusted EBITDA in the range of $455 million to $475 million.
  • Acknowledged potential first-quarter revenue decline due to seasonal dynamics.

4. Bad News, Challenges, or Points of Concern

• GAAP Net Income Decline: The decrease in GAAP net income was attributed to a one-time loss related to debt refinancing.
• Potential Competitive Pressures: Although current competitive dynamics appear stable, the company remains vigilant about future market entrants that could impact Jornay PM demand.
• Operating Expense Increases: Operating expenses rose significantly (37% year-over-year) due to investments in sales and marketing for Jornay, which could pressure margins if not managed carefully.

5. Notable Q&A Insights

• Jornay Guidance Assumptions: Growth is expected to be driven by demand stability and effective sales strategies, with no significant competitive threats currently identified.
• Sales Force Strategy: The current sales force size is deemed appropriate, but future expansions will be considered if growth is constrained.
• Nucynta and Pain Portfolio: The pain portfolio remains promotionally sensitive, and the company is prepared to adjust investments based on market conditions and competition.

Overall, Collegium Pharmaceutical demonstrated strong financial performance in 2025, with strategic initiatives in place to sustain growth, particularly for Jornay PM. However, the company faces challenges related to competitive pressures and rising operational costs.